Glycopeptide

Glycopeptide antibiotics are a class of complex glycosylated peptides that exert potent activity against Gram-positive bacteria by targeting bacterial cell-wall biosynthesis[1][2]. Mechanistically, representative glycopeptides such as vancomycin and teicoplanin recognize the terminal D-Ala-D-Ala motif of lipid II precursors, thereby blocking peptidoglycan maturation and preventing the transglycosylation and transpeptidation reactions required for cell-wall assembly[1][3][4]. This highly selective interaction underlies their clinical importance in severe infections caused by resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and enterococci[5][6]. In disease-relevant settings, the emergence of glycopeptide resistance has become a major concern because resistant bacteria remodel cell-wall precursors from D-Ala-D-Ala to D-Ala-D-Lac or D-Ala-D-Ser, markedly reducing antibiotic binding affinity and therapeutic efficacy[2][7]. Compared with first-generation glycopeptides such as vancomycin and teicoplanin, newer semisynthetic lipoglycopeptides, including telavancin, dalbavancin, and oritavancin, possess structural modifications that enhance antibacterial activity and expand pharmacological properties[5][8]. These distinctions among glycopeptide subclasses provide valuable experimental models for investigating target recognition, resistance evolution, and structure-activity relationships[5][7]. For research applications, glycopeptides remain widely used as molecular probes for studying peptidoglycan biosynthesis, lipid II-mediated pathways, and antibiotic resistance mechanisms, while chemically modified derivatives continue to support the development of next-generation antibacterial agents against drug-resistant pathogens[2][9].